New study tracks THC in kids after cannabis overdose
NCT ID NCT06017622
First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This study looks at children under 18 who come to the emergency room with severe drowsiness caused by cannabis. Researchers will measure the amount of THC and its breakdown products in their blood. The goal is to better understand how much cannabis leads to poisoning and what symptoms occur.
Why investors are watching
Anebulo Pharmaceuticals is a micro-cap company, so any clinical data can move its outlook. This observational study measures THC levels in children with cannabis-induced nervous system depression in emergency rooms. The results could show how severe these cases are and how much THC is in the blood, which may inform how the company positions its own treatments for cannabis-related emergencies.
If it works: If the study shows a clear link between THC blood levels and severe symptoms in children, Anebulo could use that evidence to support its drug candidates for reversing cannabis toxicity. That would give the company a stronger story for regulators and partners.
If it fails: The study is small, with only 36 participants, and observational data often fails to produce clear patterns. If the results are messy or show no useful relationship, the company gains little, and the stock could lose interest. Trials fail often, and this one may not change the company's prospects at all.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 36 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2023
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will consist of pediatric patients under 18 years of age who present to an emergency department with acute cannabis-induced CNS depression .
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Inclusion Criteria:The patient is younger than 18 years old. 2. The patient visits the ED with signs and symptoms of suspected acute cannabis-induced CNS depression, as evidenced by the patient suffering from clinically significant CNS depression combined with the following criteria: a) Exposure to cannabis or cannabis-derived products, or other products containing any CB1 agonist (such as Δ8-THC, HHC) within the last 12 hours, confirmed through one or more of the following: i. Positive toxicology testing, or ii. Other clinical evidence, such as reliable collateral history (e.g., from caregivers, EMS personnel, or witnesses), physical evidence (e.g., product packaging), or a consistent self-report. AND EITHER b) Symptoms are associated with cannabis exposure and developed during, or shortly after, cannabis exposure; OR c) In the judgment of investigator or designated clinician, the presentation includes symptoms consistent with acute cannabis-induced CNS depression (e.g. respiratory rate depression, increased sedative effects). 3. Blood samples are taken as part of routine clinical procedures, or the patient has an IV line through which blood can be taken. 4. The LAR is willing and able to provide consent. 5. The patient is willing and able to provide assent, if applicable and feasible, based on age and clinical condition. Exclusion criteria A potential patient who meets any of the following criteria will be excluded from participation in this study: 1. Anything that, in the opinion of the PI, would place the patient at increased risk or preclude the patient's compliance with or completion of the study. 2. Patient is presenting with signs or symptoms that are better explained by another medical condition or mental disorder, exposure to a drug other than cannabis, and, at the PI's discretion, are not induced by acute cannabis exposure. 3. Patient presenting with cannabis use disorder (CUD), cannabis hyperemesis syndrome (CHS) or cannabis withdrawal syndrome (CWS) 4. Patients who are brought in by law enforcement, i.e., cannabis intoxication associated with a vehicle accident (driving under the influence).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute cannabinoid intoxication are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cincinnati Children's Hospital
RECRUITINGCincinnati, Ohio, 45229, United States
-
Oregon Health and Sciences University
RECRUITINGPortland, Oregon, 97329, United States
-
University of Massachusetts Memorial Children's Medical Center
RECRUITINGWorcester, Massachusetts, 01605, United States